Minerva Neurosciences (NERV) Cash from Financing Activities (2013 - 2026)
Minerva Neurosciences posted quarterly Cash from Financing Activities of $1.1 million for Q1 2026, down 98.55% on a QoQ basis from $74.5 million in Q4 2025.
Minerva Neurosciences (NERV) has 12 years of Cash from Financing Activities data on file, last reported at $1.1 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities changed N/A year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $75.5 million (changed N/A YoY), and the FY2025 full-year result was $74.5 million, changed N/A from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $1.1 million, down from $74.5 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $74.5 million in Q4 2025 and bottomed at -$86691.0 in Q3 2023.
- The 3-year median for Cash from Financing Activities is $1.1 million (2026), against an average of $19.0 million.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - | 1.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.08 Mn |
| Mar 31, 2026 | 1.08 Mn |
| Dec 31, 2025 | 74.50 Mn |
| Dec 31, 2025 | 74.50 Mn |
| Sep 30, 2025 | -45,166.00 |
| Sep 30, 2025 | -45,166.00 |
| Sep 30, 2023 | -86,691.00 |
| Sep 30, 2023 | -86,691.00 |
| Jun 30, 2023 | 19.69 Mn |
| Jun 30, 2023 | 19.69 Mn |
| Mar 31, 2021 | 60.00 Mn |
| Mar 31, 2021 | 60.00 Mn |
| Sep 30, 2020 | 7.14 Mn |
| Sep 30, 2020 | 7.14 Mn |
| Jun 30, 2020 | 5.30 Mn |
| Jun 30, 2020 | 5.30 Mn |
| Mar 31, 2020 | 797,629.00 |
| Mar 31, 2020 | 797,629.00 |
| Dec 31, 2019 | -1.00 |
| Dec 31, 2019 | -1.00 |
| Mar 31, 2019 | 525,000.00 |
| Mar 31, 2019 | 525,000.00 |
| Dec 31, 2018 | 165,105.00 |
| Dec 31, 2018 | 165,105.00 |
| Sep 30, 2018 | -907,243.00 |
| Sep 30, 2018 | -907,243.00 |
| Jun 30, 2018 | -1.31 Mn |
| Jun 30, 2018 | -1.31 Mn |
| Mar 31, 2018 | -1.29 Mn |
| Mar 31, 2018 | -1.29 Mn |
| Dec 31, 2017 | -1.27 Mn |
| Dec 31, 2017 | -1.27 Mn |
| Sep 30, 2017 | 40.97 Mn |
| Sep 30, 2017 | 40.97 Mn |
| Jun 30, 2017 | -970,415.00 |
| Jun 30, 2017 | -970,415.00 |
| Mar 31, 2017 | 8.44 Mn |
| Mar 31, 2017 | 8.44 Mn |
| Dec 31, 2016 | 55,087.00 |
| Dec 31, 2016 | 55,087.00 |
| Sep 30, 2016 | -536,040.00 |
| Sep 30, 2016 | -536,040.00 |
| Jun 30, 2016 | 58.50 Mn |
| Jun 30, 2016 | 58.50 Mn |
| Mar 31, 2016 | 18.54 Mn |
| Mar 31, 2016 | 18.54 Mn |
| Jun 30, 2015 | -232,225.00 |
| Jun 30, 2015 | -232,225.00 |
| Mar 31, 2015 | 38.57 Mn |
| Mar 31, 2015 | 38.57 Mn |
| Dec 31, 2014 | -30,251.00 |
| Dec 31, 2014 | -30,251.00 |
| Sep 30, 2014 | 50.35 Mn |
| Sep 30, 2014 | 50.35 Mn |
| Jun 30, 2014 | 882,817.00 |
| Jun 30, 2014 | 882,817.00 |
| Mar 31, 2014 | 394,583.00 |
| Mar 31, 2014 | 394,583.00 |
| Dec 31, 2013 | 1.93 Mn |
| Dec 31, 2013 | 1.93 Mn |